Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-based therapeutics--the third generation

M Sleigh1

  • 1Peptide Technology Limited, N.S.W.

Australasian Biotechnology
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulated autocrine growth of CHO cells.

Cytotechnology·2008
Same author

The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion.

Growth factors (Chur, Switzerland)·1994
Same author

The evolution of the adenoviral genome.

Annals of the New York Academy of Sciences·1980
Same author

Contractility of the roots of flagella and cilia.

Nature·1979
Same author

Ciliary function of the frog oro-pharyngeal epithelium.

Cell and tissue research·1977
Same journal

The world's first brewery exclusively designed to use continuous fermentation: biotechnology history made in New Zealand.

Australasian biotechnology·1996
Same journal

Production of useful chemicals from sunflower oil by microbial biotransformation with rhizopus stolonifer NRRL 1478.

Australasian biotechnology·1996
Same journal

Industry involvement in Australian agrobiotechnology: the views of scientists.

Australasian biotechnology·1994
Same journal

The 1993 Burnet Lecture. The colony stimulating factors--discovery to clinical use.

Australasian biotechnology·1994
Same journal

Plant biotechnologies in Pacific Rim developing countries: achievements, co-operation and prospects.

Australasian biotechnology·1994
Same journal

Biotechnology in Australia in 1993.

Australasian biotechnology·1994
See all related articles

Cambridge Antibody Technology (CAT) has acquired rights to develop engineered antibody molecules called diabodies. This article explores the origins and potential of these novel antibody fragments in the rapidly advancing field of antibody engineering.

Area of Science:

  • Biotechnology
  • Immunology
  • Molecular Engineering

Background:

  • Cambridge Antibody Technology (CAT) has secured commercial development rights for a novel engineered antibody molecule.
  • Diabodies, a new class of antibody fragments, were pioneered by Dr. Greg Winter at the Medical Research Council Laboratories.

Purpose of the Study:

  • To examine the origins and developmental history of diabodies.
  • To assess the potential applications and future prospects of diabodies.
  • To contextualize diabody development within recent advancements in antibody engineering.

Main Methods:

  • Review of scientific literature and patent filings related to diabody technology.
  • Analysis of the scientific contributions of Dr. Greg Winter and the Medical Research Council.

Related Experiment Videos

  • Comparative assessment of diabodies against other emerging antibody engineering strategies.

    • Main Results:

    • Diabodies represent a significant innovation in antibody fragment engineering.
    • The commercial development rights obtained by CAT highlight the perceived potential of this technology.
    • The field of antibody engineering is characterized by rapid innovation and diversification.

    Conclusions:

    • Diabodies possess considerable potential for therapeutic and diagnostic applications.
    • Continued research and development are crucial for realizing the full potential of diabody technology.
    • The emergence of diabodies underscores the dynamic nature of antibody engineering and its impact on biotechnology.